Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) closed a previously announced private placement of pre-funded warrants, priced at-the-market under Nasdaq rules, to purchase an aggregate of 8,462,027 shares of common stock. Each pre-funded warrant and accompanying two warrants has a combined effective offering price of $0.4657.
The pre-funded warrants have an exercise price of $0.007 per share. The accompanying warrants have an initial exercise price of $0.4727 per share, become exercisable following stockholder approval, and expire five years from issuance. According to bioAffinity, gross proceeds are estimated at $4.0 million before fees, and the company will provide customary registration rights for the underlying shares.
bioAffinity Technologies (Nasdaq: BIAF) closed its previously announced private placement of pre-funded warrants to purchase an aggregate of 8,462,027 common shares, priced at-the-market under Nasdaq rules. The combined effective offering price per pre-funded warrant and accompanying two warrants is $0.4657, generating estimated gross proceeds of $4.0 million before fees and expenses.
The pre-funded warrants have an exercise price of $0.007 per share. The accompanying warrants have an initial exercise price of $0.4727 per share, will be exercisable following stockholder approval, and will expire five years from issuance. The securities were issued in a private placement under Section 4(a)(2) and/or Regulation D, with customary registration rights for the underlying shares.
bioAffinity Technologies (Nasdaq: BIAF) entered a securities purchase agreement with an institutional investor to raise an estimated $4.0 million in gross proceeds through a private placement priced at-the-market under Nasdaq rules. The company will sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock.
The combined effective offering price is $0.4727 per share plus accompanying warrants, or $0.4657 per pre-funded warrant plus accompanying warrants. Pre-funded warrants have a $0.007 exercise price. The additional warrants carry a $0.4727 exercise price, are exercisable following stockholder approval, and expire five years after issuance. Closing is expected on or about August 14, 2026, subject to customary conditions. WallachBeth Capital is acting as sole placement agent. The unregistered securities are offered under Section 4(a)(2) and/or Regulation D, and the company will provide customary registration rights for shares underlying the warrants.
bioAffinity Technologies (Nasdaq: BIAF) entered into a securities purchase agreement with an institutional investor for a private placement priced at-the-market under Nasdaq rules. The company will sell 8,462,027 shares of common stock (or pre-funded warrants in lieu) together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock.
The combined effective offering price is $0.4727 per share and accompanying warrants, or $0.4657 per pre-funded warrant and accompanying warrants. Pre-funded warrants have a $0.007 exercise price per share. The warrants carry a $0.4727 exercise price, become exercisable after stockholder approval, and expire five years from issuance. Gross proceeds are estimated at approximately $4.0 million before fees, with closing expected on or about August 14, 2026, subject to customary conditions. The securities are being issued in a private placement under Section 4(a)(2) and/or Regulation D, and the company will provide customary registration rights for shares underlying the warrants.
bioAffinity Technologies (Nasdaq: BIAF) reported Q2 2026 revenue of $1.51 million, up 19% year over year, driven mainly by higher CyPath® Lung sales, while net loss narrowed to $3.37 million from $4.06 million. CyPath Lung test volume rose 216% in Q2, with 1,097 test reports delivered in the first half of 2026 versus 390 a year earlier, and testing revenue for the period increased 159% to about $835,000.
The company expanded physician adoption, with ordering sites up 122% in Q2 and existing clients increasing orders 71% year over year. A longitudinal CyPath Lung clinical trial began enrollment at 11 sites with support from the John P. Murtha Cancer Center Research Program. bioAffinity also advanced diagnostics for asthma and COPD, reported positive preclinical data for topical siRNA-based skin cancer therapeutics, received a key Mexican patent allowance, and completed a June 2026 public offering generating approximately $3.2 million in gross proceeds. Cash and equivalents were $2.43 million at June 30, 2026.
bioAffinity Technologies (Nasdaq: BIAF) announced publication of a comprehensive clinical review and white paper by Chief Medical Officer Gordon H. Downie, MD, PhD, outlining a practical framework for integrating CyPath® Lung into pulmonary nodule evaluation and lung cancer surveillance across primary care, pulmonology and oncology.
The paper addresses the rising volume of pulmonary nodules driven by expanded screening, incidental findings and AI detection, and the need for improved risk stratification. It describes how CyPath Lung, a noninvasive sputum-based test that evaluates the lung microenvironment, has shown consistent clinical performance over three years of commercial use in helping physicians stratify malignancy risk, complement imaging and predictive models, and clarify challenging cases.
The framework proposes specialty-specific clinical pathways that incorporate CyPath Lung as an adjunct data point rather than a stand‑alone tool, emphasizing that direct analysis of sputum can reveal local immune responses, inflammation, genetic alterations and tumor biology not captured by blood-based diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) announced a collaboration with targeted proteomic platform company Pictor to jointly develop and commercialize next-generation diagnostic tests for asthma and COPD. The partnership integrates bioAffinity’s flow cytometry of sputum immune cells with Pictor’s multi-analyte cytokine profiling to deliver high-throughput, lower-cost laboratory testing aimed at characterizing airway inflammation.
bioAffinity will own intellectual property arising from the new asthma/COPD tests, while Pictor retains and extends IP related to its targeted proteomic platform. The tests are expected to launch initially as CLIA-regulated Laboratory Developed Tests (LDTs). According to the company, asthma and COPD affect more than 40 million Americans and 650 million people worldwide, with the global therapeutics market valued at about $92 billion in 2024 and projected to exceed $108 billion in 2026 and $155 billion by 2030, underscoring the commercial potential for precision diagnostics that can guide targeted and biologic therapies.
bioAffinity Technologies (Nasdaq:BIAF) reported that Q2 2026 CyPath® Lung sales volume grew more than 200% year-over-year and over 30% versus Q1 2026. Physician offices ordering CyPath® Lung increased 155% from Q2 2025, and nearly 3,000 tests have been performed since launch. The company is advancing a large-scale longitudinal CyPath® Lung study and developing additional noninvasive diagnostics for asthma and COPD.
bioAffinity Technologies (Nasdaq:BIAF) reported preclinical in vitro data showing its proprietary siRNA gene-silencing approach selectively impairs proliferation of squamous and basal skin cancer cells while leaving non-cancerous skin cells unaffected. The work targets cell surface receptors CD320 and LRP2 and is covered by U.S. Patent No. 12,305,171.
According to the company, these results support further development of a potential topical, noninvasive treatment for common cutaneous cancers, subject to additional research and regulatory review. Findings will be presented at the 2026 RNA Therapeutics Symposium.
bioAffinity Technologies (Nasdaq:BIAF) closed a previously announced public offering for $3.2 million in aggregate gross proceeds, before fees and expenses.
The offering comprised 4,000,000 common shares at $0.80 per share, or pre-funded warrants at $0.793, each exercisable for one common share. WallachBeth Capital acted as sole placement agent.